Last updated: March 1, 2026
What is the current formulation and excipient profile?
Berkley and Jensen Mucus Relief DM is an over-the-counter (OTC) cough and cold medication primarily containing dextromethorphan HBr (20 mg per dose) and guaifenesin (200 mg per dose). Its formulation targets symptomatic relief of cough and mucus.
The excipients typically include:
- Binders: Microcrystalline cellulose
- Fillers: Lactose monohydrate, corn starch
- Disintegrants: Croscarmellose sodium
- Lubricants: Magnesium stearate
- Sweeteners: Sucrose or sorbitol
- Flavoring agents: Natural and artificial flavors
- Colorants: FD&C dyes or similar
Limited detailed proprietary excipient lists are publicly available, but the formulation follows common OTC cough syrup standards.
How can excipient strategies influence product performance and compliance?
Excipients impact:
- Bioavailability: Choice of disintegrants and fillers influences dissolution and absorption.
- Stability: Excipients such as antioxidants and stabilizers can prolong shelf-life.
- Patient compliance: Flavoring and sweeteners affect taste, especially in liquid dosage forms.
- Allergenicity: Use of lactose or artificial dyes may pose allergenicity concerns.
Customizing excipients can optimize formulation stability, improve organoleptic properties, and differentiate the brand.
What commercial opportunities exist through excipient innovation?
1. Developing allergen-free formulations
Replacing common allergens such as lactose or certain dyes with hypoallergenic alternatives widens the consumer base, especially for lactose-intolerant and dye-sensitive individuals.
2. Enhancing taste and palatability
Innovating with natural sweeteners like stevia or monk fruit reduces sugar content, appealing to health-conscious consumers and regulatory trends against high sugar intake.
3. Improving stability and shelf-life
Incorporating excipients with antioxidant properties can extend shelf stability, especially for liquid formulations exposed to variable storage conditions.
4. Creating sustained or controlled-release formulations
Modifications in excipient matrix design can enable controlled release of active ingredients, providing longer duration of action and enhanced user convenience.
5. Scaling formulations for different delivery routes
Developing excipient profiles suitable for syrups, dissolvable tablets, or nasal sprays opens cross-market opportunities.
What regulatory considerations drive excipient strategy?
- FDA Guidance: Excipients used in OTC products are subject to monographs or must be Generally Recognized As Safe (GRAS).
- Labeling Requirements: Transparency about excipients (e.g., allergen labeling) influences formulation choices.
- International Regulations: Variations across markets (e.g., EMA, Health Canada) impact excipient selection and allowable additives.
Aligning excipient strategy with regulatory standards can prevent delays and facilitate market entry.
What are key challenges in excipient development?
- Balancing cost and performance
- Ensuring global regulatory compliance
- Managing allergen and sensitivity issues
- Maintaining product stability and bioavailability
- Meeting consumer demand for natural or allergen-free ingredients
How can manufacturers leverage excipient innovation?
- Incorporate excipients with added functionality, like taste-masking or enhanced stability.
- Use bio-based or biodegradable excipients to meet sustainability trends.
- Develop proprietary excipient blends to create product differentiation.
- Partner with excipient suppliers to access novel formulations.
Conclusion
Excipient optimization in Berkley and Jensen Mucus Relief DM provides avenues for formulation enhancement, regulatory compliance, and market expansion. Strategic innovation in excipient selection and formulation can lead to improved product stability, patient adherence, and brand loyalty. Companies should align excipient strategies with regulatory standards, consumer preferences, and technological advances to unlock competitive advantages.
Key Takeaways
- Excipient choice influences drug stability, bioavailability, and patient compliance.
- Formulation modifications, such as allergen-free or natural sweeteners, expand market reach.
- Stability and controlled-release innovations open new product categories.
- Regulatory requirements heavily influence excipient selection.
- Leveraging excipient innovation requires balancing cost, performance, and consumer preferences.
FAQs
1. Can natural excipients replace conventional excipients in OTC cough medications?
Yes. Natural excipients like plant-based binders and natural sweeteners can replace traditional fillers and sweeteners, appealing to consumers seeking cleaner labels. However, regulatory approval and stability considerations must be addressed.
2. How does excipient selection affect shelf life for liquid formulations?
Excipients such as antioxidants and stabilizers help prevent degradation of active ingredients, thereby extending shelf life. Proper selection minimizes microbial growth and chemical instability.
3. Are there regulatory limits on certain excipients in OTC cough medicines?
Yes. For example, dyes and preservatives are regulated, and approved excipients must meet FDA monographs or GRAS status. Exceeding limits can delay approval or require additional testing.
4. What role does consumer preference play in excipient strategy?
Consumer preferences for sugar-free, allergen-free, and natural ingredients drive formulation choices. Transparency and labeling are also critical for market acceptance.
5. How can innovation in excipients differentiate a product in a competitive OTC market?
Innovation can improve drug delivery, taste, stability, and manufacturing efficiency, creating unique selling points. Proprietary excipient blends can also serve as barriers to competitors.
References
[1] U.S. Food and Drug Administration. (2022). OTC Monograph Regulating Excipients. Retrieved from https://www.fda.gov/cosmetics/cosmetic-products/excipients-regulation-over-counter-products
[2] Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (2009). Handbook of pharmaceutical excipients (6th ed.). Pharmaceutical Press.
[3] European Medicines Agency. (2022). Guideline on excipients in the Labeling and Packaging of Medicinal Products. EMA/CHMP/QWP/245072/2019.
